Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Burkitt Lymphoma 9Vomiting 5Nausea 5Lymphoma, Mantle-Cell 4Hodgkin Disease 4Breast Neoplasms 4Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Leukemia, Biphenotypic, Acute 3Immunoglobulin Light-chain Amyloidosis 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmacytoma 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Hairy Cell 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Testicular Neoplasms 1

Interventions

venetoclax 4fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 3ibrutinib 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Melphalan 2Dexamethasone 2pomalidomide 1pembrolizumab 1obinutuzumab 1ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1auricularum 1acalabrutinib 1Sirolimus 1RG7388 1Nivolumab 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Chromosome 17 deletion × dexamethasone acetate × Clear all
NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
33 enrolled 26 charts
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡